|Hospital of the Future and its challenges
Renaud Mazy, Cliniques universitaires Saint-Luc
|The recent Belgian Pact of Medical Technologies
Marnix Denys, beMedTech
|Medical technologies at the crossroads of key enabling technologies
Willem Dhooge, FlandersBio
| Boost your project with the MedTech Accelerator program
Azèle Mathieu, lifetech.brussels
|Improve implant effectiveness by controlled bone 3D shaping
Gregory Nolens, CERHUM
|Why the in silico technology accelerates and amplifies the personalized medicine revolution?
Thierry Marchal, ANSYS
|Innovative polymer processing – Electrospinning and its usage in drug delivery and devices
Gareth Williams, University College London
|Implementation of innovative manufacturing processes within a strict regulatory framework
Marilys Blanchy, RESCOLL
|Louvain Bionics: Research and innovation for the patient
Benoit Herman, Louvain Bionics
|Thinking globally during medical device development: translating great ideas into commercial success
Jean-Marc De Verteuil, NAMSA
|mHealth: the legal journey
Christel Brion & Heidi Waem, NautaDutilh
|The last hurdle for innovation: market access – an upfront thought
Christian Huyghe, HealthProAccess
|Fournier-Majoie Foundation – Entrepreneurship against cancer
Jérôme Majoie, Fournier-Majoie Foundation
Hospital of the Future and its challenges
Renaud Mazy, CEO, Cliniques universitaires Saint-Luc
Leveraging recent technological breakthroughs, the hospital of the future will have to develop and integrate new tools to support doctors and nurses in the treatment of their patients. Based on connected medical devices, diagnostic tools or other applications, innovation is an integral part of the hospital environment where humanity is so close to technology. Patients themselves are becoming more and more connected and are expecting the same from the hospital. This revolution implies many challenges in terms of digitization of patient care, especially data management, like at Cliniques universitaires Saint-Luc, where most of the care related information is being centralized in a single electronic medical record.
The recent Belgian Pact of Medical Technologies
Marnix Denys, Director, beMedTech
Maggie De Block, minister of Social Affairs and Healthcare and the Belgian federation of the industry of medical technologies closed a pact of the future for the medical technologies in October 2016. The main goal of the Pact Medical Technologies is to improve on the safety of and access to medical technologies. The pact contains five chapters: transversal measures that are valid for all medical technologies and specific measures for implants, in-vitro diagnostics, consumables and medical equipment. The pact counts 32 actions, relating to all segments of medical technologies and resulting from a close cooperation between the parties. The government and industry are committed to bring more clarity, a better follow-up and to reduce complexity in the environment of medical technologies so that safety, quality and access can improve and be easier controlled. This session provides an introduction of the Belgian landscape as well as a summary of the main actions in the pact.
Medical technologies at the crossroads of key enabling technologies
Willem Dhooge, Program Manager, FlandersBio
The healthcare management system (HMS) in many parts of the Western world is in a perfect storm. Never before so many significant factors have together impacted the HMS business space. An ageing population, global travel and migration, concentration of people in megacities, life style evolutions and consumerism impact an increasingly untenable healthcare cost. In order to keep the HMS cost sustainable, solutions for this trend lie in a paradigm shift from curative blockbuster driven medicine to tailored prediction, prevention and precision medicine and a further evolution from a hospital-centric towards a home based patient-centric care system. These evolutions are in part the direct result from radical technological breakthroughs in life sciences and from solutions brought about by advanced micro/nano-technology platforms.
As innovation is likely to occur at the borderlines between different industries and technologies, facilitation and acceleration of new combinations along and across value chains represent a source for potential innovation and growth for the enterprises involved. Belgium has a long and successful tradition and track record in the pharmaceutical and biotech industry, leveraged in Flanders by the strategic research centre VIB among others. The same applies to the field of micro & nanolectronics with IMEC as a world leading research institute and the centre of an ecosystem driven by numerous R&D intensive companies.
The development of new industrial value chains in the healthcare management system calls for the collaboration and integration of different innovation actors, including large enterprises and especially SMEs, across different sectors towards the implementation of a joint vision. To achieve this, FlandersBio & DSP Valley, the industrial cluster organisations for the biotech and life sciences and micro & nano-electronics respectively, have joined forces. Each cluster has a strong track record in supporting SMEs regional ecosystem by focusing on the growth and maturation of the involved SMEs and boosting the emergence of R&D collaborative projects and the SME development.
Boost your project with the MedTech Accelerator program
Azèle Mathieu, Managing Director, lifetech.brussels
As you may know, Health Tech is a booming sector in Belgium, the leader of Belgian NTBFs (New Technological Based Firms), ahead of FinTech, and representing 10% of these Belgian NTBFs (source: SIRRIS). In addition it is the Belgian sector where the amount of academic spin-offs is the highest (source: SIRRIS). This clearly shows the importance of the interrelatedness between scientific research, innovation and entrepreneurship in the field. Belgium has clearly the potential to become one of the most innovative hotspot in medical devices as our country is in the biopharma field.
We want to encourage innovation in medical devices, at each level of the value chain, from the very early development of a seed project to the implementation and deployment of a large business. We started with Medical Devices start-ups: now Belgium is one of the very first European countries to have launched a start-up accelerator program specifically dedicated to MedTech start-ups (MedTech Accelerator Program). But why an accelerator? What are the objectives? Who are the experts? What can you get out of this program? What is the evolution of the sector?… a number of questions that we will have the pleasure to evoke during this session.
Improve implant effectiveness by controlled bone 3D shaping
Grégory Nolens, PhD, CEO, CERHUM
3D printing has known several developments in the additive manufacturing world. It opens now new opportunities in several markets like medical, aerospace, electronics, luxury, food, biotechnologies, …
This presentation will focus on actual applications of 3D printing bioceramics and bone for medical applications. Some medical cases will be highlighted showing that 3D printing of artificial bone can improve implant performance. Focus will be made on field proven materials, design opportunities, machine process and post process. Perspectives will be showed and discussed and confronted to market reality.
Why the in silico technology accelerates and amplifies the personalized medicine revolution?
Thierry Marchal, Global Industry Director, ANSYS
As the cost of healthcare is sky rocketing around the world, the XXIst century medicine must take advantage of high tech evolution to become personalized, participatory predictive and preventive (P4). To address the dilemma of combining necessary disruptive innovations with maximized patient safety, medical device innovators have largely embraced the in silico technology, wholeheartedly encouraged by US and European governments and regulatory agencies (FDA, EMA, …). How could local innovators play a leading role in this important revolution?
Back to top
Innovative polymer processing – Electrospinning and its usage in drug delivery and devices
Dr Gareth Williams, Senior Lecturer (Associate Professor) in Pharmaceutics, University College London
Electrospinning is a facile yet versatile technique which can be used to prepare polymer fibres with dimensions on the nanoscale. It involves preparing a solution of a polymer and a functional component in a volatile solvent, and then using electrical energy to evaporate the solvent. This yields one-dimensional polymer-based fibres with the functional component embedded. Electrospun nanofibres have been widely explored in drug delivery to achieve goals such as accelerating the dissolution rate of drugs, targeting delivery to a particular part of the body, or delivering a drug at a constant rate. Beyond drug delivery systems, electrospun fibres also have great potential in tissue engineering, for instance in the development of bioresorbable scaffolds. In this presentation, some recent studies using these fibres for both applications will be discussed.
Implementation of innovative manufacturing processes within a strict regulatory framework
Marilys Blanchy, R&D Project Manager, RESCOLL
New processes are constantly developed for diseases treatment, drug release or regenerative medicine. Important developments have been carried out in the field of electrospinning, surface treatment or 3D printing among others. Although being very innovative these technologies have to be implemented within a strict regulatory framework. Depending on the field of application, the product specification must achieve the expected level of performance while complying with the involved legal constraints. During her presentation, Marilys will answer the following questions: Which regulation should be taken into consideration? How to validate those processes? How to validate the product performances?
Louvain Bionics – Research and innovation for the patient
Benoit Herman, Coordinator, Louvain Bionics
Louvain Bionics is a center of interdisciplinary expertise created in 2014 to bring together UCL researchers interested in questions of movement and robotic assistance to enhance the knowledge and skills in areas such as surgical assistance and diagnostic and rehabilitation. The ambition of Louvain Bionics is to allow the patient to benefit from the best research advances in robotics science and technology, and more generally, bionics.
As highlighted in this talk through the examples of Axinesis and 3D Side spin-off companies, Louvain Bionics identifies, encourages and coordinates collaborative research projects between different disciplines (engineering, medicine, neuroscience, sports sciences, psychology, philosophy and ethics) for scientific, academic, and clinical purpose to develop and validate medical devices and therapies from the laboratory to the bedside of patients.
Thinking globally during medical device development: translating great ideas into commercial success
Jean-Marc De Verteuil, EMEA Marketing Manager, NAMSA
This presentation will look at how to determine a “get to market” strategy for medical devices, focusing on how to effectively demonstrate biological safety and performance, and global strategic considerations for specific markets. Key points will be understanding how regulatory agencies think and sharing case studies of common mistakes and pitfalls that can cause delays in submissions.
mHealth: the legal journey
Christel Brion and Heidi Waem, Senior Associates, NautaDutilh
On the legal point of view mobile Health raises many questions:
What is the legal framework I must comply with (eg. medical device regulatory framework, fair trade practices and consumer protection, data protection)? How should I protect my intellectual property assets? What are my potential liabilities and (how) can they be mitigated?
During their presentation, Christel and Heidi will address all those specific aspects that must be taken into account in the development of any mHealth project.
The last hurdle for innovation: market access – an upfront thought
Christian Huyghe, HealthProAccess
Getting market access is a crucial turning point for many companies. Getting your medical device reimbursed by the government makes a project viable or not. Market access means the process to get a medical technology approved to be reimbursed by the government. These reimbursement decisions in Europe are made on the country level, whereas for medical devices or diagnostics, this can be at a regional or even hospital level which makes it all the more complex. Defining the medical need to which you want to reply, is an important step in securing market access after approval. Will your innovation be welcomed within 5 or 10 years? Authorities who will evaluate your technology will all have very different backgrounds. You have to take this into consideration. Try to describe your innovation as simple as possible. Make sure that people understand what you want to bring to healthcare. Market access is more than just knowing the systems of the different countries but also being able to estimate the complexity of the different systems and then being able to assure funding. You need the right expertise and a lot of experience to get market access for your product. It is really something you cannot learn at university. You can study the regulations and the rules, but how to apply them is to learn from doing in the field. It requires a lot of fighting spirit not to be dominated by the stubbornness of regulators. A number of simple cases will be presented to make the subject more “real life”.
Entrepreneurship against cancer
Jérôme Majoie, Fournier-Majoie Foundation
For over ten years, Fournier-Majoie Foundation have funded and supported 14 researchers/innovators/entrepreneurs in the area of oncology. Fundings range from 150,000 euros to 1,000,000 euros. If and only the project is successful, part of the income must be donated to the foundation in order to fund other projects. This gives entrepreneurs the chance to be part of the virtuous circle that supports promising projects aiming to give patients access to innovation.